Cover Image
Market Research Report

Activated PI3K Delta Syndrome (APDS) Therapeutic Market (Opportunities Assessments, Market Dynamics, Pipeline Analysis, Current Market Size and Market Forecast 2018 - 2028)

Published by GervanoRA Data Services LLP Product code 769578
Published Content info 170 Pages
Delivery time: 1-2 business days
Price
Back to Top
Activated PI3K Delta Syndrome (APDS) Therapeutic Market (Opportunities Assessments, Market Dynamics, Pipeline Analysis, Current Market Size and Market Forecast 2018 - 2028)
Published: June 1, 2017 Content info: 170 Pages
Description

GervanoRA's Market Estimation report "Activated PI3K Delta Syndrome (APDS): Opportunity Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analysis, Current Market Size and Market Forecast (2019-2025)" analyzed the current and upcoming opportunities in the Activated PI3K Delta Syndrome (APDS) area by assessing the drug market, covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Activated PI3K Delta Syndrome (APDS) industry. The report has been divided into segments like Disease Overview, Market Overview, Pipeline Analysis and Clinical Trials summary to provide in depth insights about the market dynamics and ongoing R&D in the Activated PI3K Delta Syndrome (APDS) area. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Molecules by Geography, Pipeline Molecules by Drug Class, Pipeline Molecules by Mechanism of Action and Pipeline Molecules by Stage of development. The report evaluated the current market scenario by estimating the market value with respect to Activated PI3K Delta Syndrome (APDS) Drug Class, Route of Administration and Age Group. Report primarily focuses on the patent analysis of the key marketed and pipeline drugs to provide a brief understanding about the market opportunities in the Activated PI3K Delta Syndrome (APDS) competitive environment. We have also prognosticated the Activated PI3K Delta Syndrome (APDS) market share in 11 Major Markets to aid our clients with the commercial and economic opportunities in these geographies.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on

  • Epidemiology and Epidemiology forecast 2019 - 2025
  • Market Dynamics with Coverage of Deals (Mergers, Acquisitions, Partnering, Collaborations etc.)
  • Estimated Pipeline Drug Approval Timelines
  • Clinical Trials Summary
  • Current and Future Competitive Landscape
  • Key Company Profiles with SWOT Analysis
  • Emerging Company Profiles with Opportunity Assessments
  • Pipeline Drug Descriptions along with Development milestones (Past and Future)
  • University Pipeline Molecules & In-Licensing/Out Licensing Opportunities.
Table of Contents
Product Code: GERPHME171

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. REPORT DESCRIPTION
  • 1.2. METHODOLOGY
  • 1.3. UPCOMING AND OTHER AVAILABLE REPORTS
  • 1.4. ABOUT US: GERVANORA DATA SERVICES

2. EXECUTIVE SUMMARY

  • 2.1. MARKET SNAPSHOT, 2019-2025
  • 2.2. KEY EVENTS IN ACTIVATED PI3K DELTA SYNDROME (APDS) MARKET, 2015-2030
  • 2.3. PRODUCT LIFE CYCLE MANAGEMENT (LCM) STRATEGIES
  • 2.4. KEY MAJOR FINDINGS
    • 2.4.1. DRIVERS
    • 2.4.2. RESTRAINTS
    • 2.4.1. UNMET NEEDS AND OPPORTUNITIES

3. DISEASE OVERVIEW

  • 3.1. DISEASE DEFINITION & SYMPTOMS
    • 3.1.1. CLINICAL MANIFESTATIONS
    • 3.1.2. PATHOGENESIS
  • 3.2. DISEASE CAUSE AND CLASSIFICATION
  • 3.3. DISEASE DIAGNOSIS
  • 3.4. TREATMENT ALGORITHM AND GUIDELINES
  • 3.5. EPIDEMIOLOGY AND DISEASE BURDEN
  • 3.6. EPIDEMIOLOGY FORECAST
    • 3.6.1. FORECAST METHODOLOGY AND ASSUMPTION
    • 3.6.2. PROBABILISTIC EPIDEMIOLOGY FORECAST

4. MARKET OVERVIEW

  • 4.1. GOVERNMENT REGULATORY DYNAMICS AND IMPACT
  • 4.2. PRICING AND REIMBURSEMENT
  • 4.3. DEALS (MERGERS/ ACQUISITIONS / COLLABORATIONS)
  • 4.4. NEW DRUG APPROVALS (US FDA) SINCE 2010
  • 4.5. NEW DRUG APPROVALS (EMA) SINCE 2010
  • 4.6. PATENT ANALYSIS (EXPIRES AND GENERICIZATION)

5. PIPELINE ANALYSIS AND ESTIMATED APPROVAL TIMELINE

  • 5.1. PIPELINE ANALYSIS BY STAGE OF DEVELOPMENT
    • 5.1.1. PRE-REGISTRATION (FILED) MOLECULES
    • 5.1.2. PHASE 3 MOLECULES
    • 5.1.3. PHASE 2 MOLECULES
    • 5.1.4. PHASE 1 MOLECULES
    • 5.1.5. PRECLINICAL MOLECULES
    • 5.1.6. EARLY R&D MOLECULES
    • 5.1.7. INACTIVE AND TERMINATED MOLECULES
  • 5.2. PIPELINE ANALYSIS BY GEOGRAPHY
    • 5.2.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.3. PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION
    • 5.3.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.4. PIPELINE ANALYSIS BY DRUG CLASS
    • 5.4.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.5. PIPELINE ANALYSIS BY MECHANISM OF ACTION
    • 5.5.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.6 PIPELINE ANALYSIS BY UNIVERSITIES AND INSTITUTES
  • 5.7. ESTIMATED APPROVAL TIMELINES
    • 5.7.1. METHODOLOGY
    • 5.7.2. ESTIMATED APPROVAL TIMELINES US & EX-US

6. ACTIVATED PI3K DELTA SYNDROME (APDS) CLINICAL TRIALS SUMMARY

  • 6.1. ACTIVATED PI3K DELTA SYNDROME (APDS) PIPELINE ANALYSIS BY CLINICAL TRIALS RESULTS
    • 6.1.1. KEY PHASE 3 RESULTS
    • 6.1.2. KEY PHASE 2 RESULTS
  • 6.2. ONGOING CLINICAL TRIALS SUMMARY
    • 6.2.1. KEY PHASE 3 ONGOING CLINICAL TRIALS SUMMARY
    • 6.2.2. KEY PHASE 2 ONGOING CLINICAL TRIALS SUMMARY
    • 6.2.3. KEY PHASE 1 ONGOING CLINICAL TRIALS SUMMARY
  • 6.3 PLANNED CLINICAL TRIALS SUMMARY
  • 6.4. RECENTLY COMPLETED CLINICAL TRIALS SUMMARY
    • 6.4.1. RECENTLY COMPLETED PHASE 3 CLINICAL TRIALS SUMMARY
    • 6.4.2. RECENTLY COMPLETED PHASE 2 CLINICAL TRIALS SUMMARY
    • 6.4.3. RECENTLY COMPLETED PHASE 1 CLINICAL TRIALS SUMMARY

7. ACTIVATED PI3K DELTA SYNDROME (APDS) MARKET BY DRUG CLASS

8. ACTIVATED PI3K DELTA SYNDROME (APDS) MARKET BY ROUTE OF ADMINISTRATION

9. ACTIVATED PI3K DELTA SYNDROME (APDS) MARKET BY GEOGRAPHY

  • 9.1. UNITED STATES
    • 9.1.1. MARKET TRENDS AND GROWTH FACTORS
    • 9.1.2. UNMET NEEDS AND OPPORTUNITIES
    • 9.1.3. US ACTIVATED PI3K DELTA SYNDROME (APDS) MARKET SIZE (2018), FORECAST (2019-2025)
  • 9.2. UNITED KINGDOM
    • 9.2.1. MARKET TRENDS AND GROWTH FACTORS
    • 9.2.2. UNMET NEEDS AND OPPORTUNITIES
    • 9.2.3. UK ACTIVATED PI3K DELTA SYNDROME (APDS) MARKET SIZE (2018), FORECAST (2019-2025)
  • 9.3. GERMANY
    • 9.3.1. MARKET TRENDS AND GROWTH FACTORS
    • 9.3.2. GERMANY ACTIVATED PI3K DELTA SYNDROME (APDS) MARKET SIZE (2018), FORECAST (2019-2025)
  • 9.4. FRANCE
    • 9.4.1. MARKET TRENDS AND GROWTH FACTORS
    • 9.4.2. UNMET NEEDS AND OPPORTUNITIES
    • 9.4.3. FRANCE ACTIVATED PI3K DELTA SYNDROME (APDS) MARKET SIZE (2018), FORECAST (2019-2025)
  • 9.5. ITALY
    • 9.5.1. MARKET TRENDS AND GROWTH FACTORS
    • 9.5.2. UNMET NEEDS AND OPPORTUNITIES
    • 9.5.3. ITALY ACTIVATED PI3K DELTA SYNDROME (APDS) MARKET SIZE (2018), FORECAST (2019-2025)
  • 9.6. SPAIN
    • 9.6.1. MARKET TRENDS AND GROWTH FACTORS
    • 9.6.2. UNMET NEEDS AND OPPORTUNITIES
    • 9.6.3. SPAIN ACTIVATED PI3K DELTA SYNDROME (APDS) MARKET SIZE (2018), FORECAST (2019-2025)
  • 9.7. JAPAN
    • 9.7.1. MARKET TRENDS AND GROWTH FACTORS
    • 9.7.2. UNMET NEEDS AND OPPORTUNITIES
    • 9.7.3. JAPAN ACTIVATED PI3K DELTA SYNDROME (APDS) MARKET SIZE (2018), FORECAST (2019-2025)
  • 9.8. CHINA
    • 9.8.1. MARKET TRENDS AND GROWTH FACTORS
    • 9.8.2. UNMET NEEDS AND OPPORTUNITIES
    • 9.8.3. CHINA ACTIVATED PI3K DELTA SYNDROME (APDS) MARKET SIZE (2018), FORECAST (2019-2025)
  • 9.9. INDIA
    • 9.9.1. MARKET TRENDS AND GROWTH FACTORS
    • 9.9.2. UNMET NEEDS AND OPPORTUNITIES
    • 9.9.3. INDIA ACTIVATED PI3K DELTA SYNDROME (APDS) MARKET SIZE (2018), FORECAST (2019-2025)
  • 9.10. BRAZIL
    • 9.10.1. MARKET TRENDS AND GROWTH FACTORS
    • 9.10.2. UNMET NEEDS AND OPPORTUNITIES
    • 9.10.3. BRAZIL ACTIVATED PI3K DELTA SYNDROME (APDS) MARKET SIZE (2018), FORECAST (2019-2025)
  • 9.11. RUSSIA
    • 9.11.1. MARKET TRENDS AND GROWTH FACTORS
    • 9.11.2. UNMET NEEDS AND OPPORTUNITIES
    • 9.11.3. RUSSIA ACTIVATED PI3K DELTA SYNDROME (APDS) MARKET SIZE (2018), FORECAST (2019-2025)
  • 9.12. ROW
    • 9.12.1. MARKET TRENDS AND GROWTH FACTORS
    • 9.12.2. UNMET NEEDS AND OPPORTUNITIES
    • 9.12.3. ROW MARKET SIZE (2018), FORECAST (2019-2025)

10. CURRENT AND FUTURE COMPETITIVE LANDSCAPE

  • 10.1. COMPANIES
    • 10.1.1. ESTABLISHED COMPANY PROFILES WITH SWOT ANALYSIS
    • 10.1.2. TOP 20 EMERGING COMPANIES IN THE ACTIVATED PI3K DELTA SYNDROME (APDS) AREA
  • 10.2. UNIVERSITIES AND INSTITUTES

11. ABBREVIATIONS

LIST OF TABLES

  • TABLE 1: REPORT HIGHLIGHTS IN NUMERICALS
  • TABLE 2: LIST OF FDA APPROVED DRUGS FOR ACTIVATED PI3K DELTA SYNDROME (APDS)
  • TABLE 3: LIST OF EMA APPROVED DRUGS FOR ACTIVATED PI3K DELTA SYNDROME (APDS)
  • TABLE 4: ACTIVATED PI3K DELTA SYNDROME (APDS) EPIDEMIOLOGY (2018), FORECAST (2019-2025)
  • TABLE 5: MAJOR ACQUISITIONS AND MERGERS IN ACTIVATED PI3K DELTA SYNDROME (APDS) AREA
  • TABLE 6: MAJOR COLLABORATIVE AGREEMENTS IN ACTIVATED PI3K DELTA SYNDROME (APDS) AREA
  • TABLE 7: MAJOR LICENSING AGREEMENTS IN ACTIVATED PI3K DELTA SYNDROME (APDS) AREA
  • TABLE 8: MAJOR PARTNERSHIPS AND JOINT VENTURE IN ACTIVATED PI3K DELTA SYNDROME (APDS) AREA
  • TABLE 9: MAJOR GRANTS AND FUNDINGS IN ACTIVATED PI3K DELTA SYNDROME (APDS) AREA
  • TABLE 10: MAJOR ALLIANCE DEALS IN ACTIVATED PI3K DELTA SYNDROME (APDS) AREA
  • TABLE 11: US FDA APPROVED DRUGS FOR ACTIVATED PI3K DELTA SYNDROME (APDS) SINCE 2010
  • TABLE 12: EX-US APPROVED DRUGS FOR ACTIVATED PI3K DELTA SYNDROME (APDS) SINCE 2010
  • TABLE 13: PRE-REGISTRATION (FILED) MOLECULES IN THE ACTIVATED PI3K DELTA SYNDROME (APDS) DRUG PIPELINE
  • TABLE 14: PHASE 3 MOLECULES IN THE ACTIVATED PI3K DELTA SYNDROME (APDS) DRUG PIPELINE
  • TABLE 15: PHASE 2 MOLECULES IN THE ACTIVATED PI3K DELTA SYNDROME (APDS) DRUG PIPELINE
  • TABLE 16: PHASE 1 MOLECULES IN THE ACTIVATED PI3K DELTA SYNDROME (APDS) DRUG PIPELINE
  • TABLE 17: PRECLINICAL MOLECULES IN THE ACTIVATED PI3K DELTA SYNDROME (APDS) DRUG PIPELINE
  • TABLE 18: EARLY R&D MOLECULES IN THE ACTIVATED PI3K DELTA SYNDROME (APDS) DRUG PIPELINE
  • TABLE 19: TERMINATED AND INACTIVE MOLECULES IN THE ACTIVATED PI3K DELTA SYNDROME (APDS) DRUG PIPELINE
  • TABLE 20: ACTIVATED PI3K DELTA SYNDROME (APDS) DRUG PIPELINE MOLECULES BY ROUTE OF ADMINISTRATION
  • TABLE 21: ACTIVATED PI3K DELTA SYNDROME (APDS) DRUG PIPELINE MOLECULES OVERVIEW BY DRUG CLASS
  • TABLE 22: ACTIVATED PI3K DELTA SYNDROME (APDS) DRUG PIPELINE MOLECULES BY UNIVERSITIES
  • TABLE 23: ACTIVATED PI3K DELTA SYNDROME (APDS) DRUG PIPELINE MOLECULES BY INSTITUTES
  • TABLE 24: ESTIMATED APPROVAL TIMELINES OF PIPELINE MOLECULES
  • TABLE 25: KEY PHASE 3 ONGOING CLINICAL TRIALS
  • TABLE 26: KEY PHASE 2 ONGOING CLINICAL TRIALS
  • TABLE 27: KEY PHASE 1 ONGOING CLINICAL TRIALS
  • TABLE 28: PLANNED CLINICAL TRIALS FOR THE ACTIVATED PI3K DELTA SYNDROME (APDS) AREA
  • TABLE 29: RECENTLY COMPLETED PHASE 3 CLINICAL TRIALS
  • TABLE 30: RECENTLY COMPLETED PHASE 2 CLINICAL TRIALS
  • TABLE 31: RECENTLY COMPLETED PHASE 1 CLINICAL TRIALS
  • TABLE 32: GLOBAL ACTIVATED PI3K DELTA SYNDROME (APDS) MARKET BY DRUG CLASS (2019-2025)
  • TABLE 33: GLOBAL ACTIVATED PI3K DELTA SYNDROME (APDS) MARKET BY ROA (2019-2025)
  • TABLE 34: STRENGTH, DOSAGE AND ROA OF ACTIVATED PI3K DELTA SYNDROME (APDS) DRUGS
  • TABLE 35: TOP TEN COUNTRIES/TERRITORIES FOR NUMBER OF NEW CASES OF ACTIVATED PI3K DELTA SYNDROME (APDS) PER YEAR
  • TABLE 36: GLOBAL ACTIVATED PI3K DELTA SYNDROME (APDS) MARKET BY GEOGRAPHY, MARKET SIZE (2018), FORECAST (2019-2025)
  • TABLE 37: US MARKET SIZE (2018), FORECAST (2019-2025)
  • TABLE 38: UK MARKET SIZE (2018), FORECAST (2019-2025)
  • TABLE 39: GERMANY MARKET SIZE (2018), FORECAST (2019-2025)
  • TABLE 40: FRANCE MARKET SIZE (2018), FORECAST (2019-2025)
  • TABLE 41: ITALY MARKET SIZE (2018), FORECAST (2019-2025)
  • TABLE 42: SPAIN MARKET SIZE (2018), FORECAST (2019-2025)
  • TABLE 43: JAPAN MARKET SIZE (2018), FORECAST (2019-2025)
  • TABLE 44: CHINA MARKET SIZE (2018), FORECAST (2019-2025)
  • TABLE 45: INDIA MARKET SIZE (2018), FORECAST (2019-2025)
  • TABLE 46: BRAZIL MARKET SIZE (2018), FORECAST (2019-2025)
  • TABLE 47: RUSSIA MARKET SIZE (2018), FORECAST (2019-2025)
  • TABLE 48: ROW MARKET SIZE (2018), FORECAST (2019-2025)
  • TABLE 49: LIST OF ESTABLISHED COMPANIES IN THE ACTIVATED PI3K DELTA SYNDROME (APDS) AREA
  • TABLE 50: LIST OF EMERGING COMPANIES IN THE ACTIVATED PI3K DELTA SYNDROME (APDS) AREA
  • TABLE 51: COMPETITIVE OPPORTUNITIES, UNIVERSITIES
  • TABLE 52: COMPETITIVE OPPORTUNITIES, INSTITUTES

(ABOVE MENTIONED TABLES ARE A FEW AMONG THE TOTAL 102 TABLES IN THE REPORT)

LIST OF FIGURES:

  • FIGURE 1: GLOBAL ACTIVATED PI3K DELTA SYNDROME (APDS) MARKET 2019-2025: MARKET SNAPSHOT
  • FIGURE 2: GLOBAL ACTIVATED PI3K DELTA SYNDROME (APDS) MARKET BY GEOGRAPHY 2018 V/S 2025
  • FIGURE 3: ACTIVATED PI3K DELTA SYNDROME (APDS) MARKET BY ROA, 2018
  • FIGURE 4: ACTIVATED PI3K DELTA SYNDROME (APDS) MARKET BY AGE GROUP, 2018
  • FIGURE 5: KEY INFLECTION POINTS IN ACTIVATED PI3K DELTA SYNDROME (APDS) MARKET (2015-2030)
  • FIGURE 6: ACTIVATED PI3K DELTA SYNDROME (APDS) MAJOR FINDINGS
  • FIGURE 7: MEDICAL EXPENDITURES FOR ACTIVATED PI3K DELTA SYNDROME (APDS)
  • FIGURE 8: ACTIVATED PI3K DELTA SYNDROME (APDS) EPIDEMIOLOGY (2018), FORECAST (2019-2025)
  • FIGURE 9: OVERALL DEALS ACTIVITY IN ACTIVATED PI3K DELTA SYNDROME (APDS) AREA
  • FIGURE 10: GEOGRAPHY WISE BREAK UP V/S DEAL TYPE
  • FIGURE 11: ACTIVATED PI3K DELTA SYNDROME (APDS) DRUG PIPELINE ANALYSIS BY STAGES OF DEVELOPMENT
  • FIGURE 12: ACTIVATED PI3K DELTA SYNDROME (APDS) DRUG PIPELINE ANALYSIS BY GEOGRAPHY
  • FIGURE 13: ACTIVATED PI3K DELTA SYNDROME (APDS) DRUG PIPELINE ANALYSIS BY STAGES OF DEVELOPMENT V/S GEOGRAPHIES
  • FIGURE 14: ACTIVATED PI3K DELTA SYNDROME (APDS) DRUG PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION
  • FIGURE 15: ACTIVATED PI3K DELTA SYNDROME (APDS) DRUG PIPELINE ANALYSIS BY DRUG CLASS
  • FIGURE 16: ONGOING CLINICAL TRIALS SPLIT-UP BY HSD
  • FIGURE 17: RECENTLY COMPLETED CLINICAL TRIALS SPLIT-UP BY HSD
  • FIGURE 18: RECENTLY COMPLETED CLINICAL TRIALS SPLIT-UP BY MAJOR COMPANIES
  • FIGURE 19: GRAPHICAL REPRESENTATION OF GLOBAL ACTIVATED PI3K DELTA SYNDROME (APDS) MARKET BY DRUG CLASS
  • FIGURE 20: GRAPHICAL REPRESENTATION OF GLOBAL ACTIVATED PI3K DELTA SYNDROME (APDS) MARKET BY ROA
  • FIGURE 21: GRAPHICAL REPRESENTATION, US MARKET SIZE 2018 V/S 2025
  • FIGURE 22: GRAPHICAL REPRESENTATION, UK MARKET SIZE 2018 V/S 2025
  • FIGURE 23: GRAPHICAL REPRESENTATION, GERMANY MARKET SIZE 2018 V/S 2025
  • FIGURE 24: GRAPHICAL REPRESENTATION, FRANCE MARKET SIZE 2018 V/S 2025
  • FIGURE 25: GRAPHICAL REPRESENTATION, ITALY MARKET SIZE 2018 V/S 2025
  • FIGURE 26: GRAPHICAL REPRESENTATION, SPAIN MARKET SIZE 2018 V/S 2025
  • FIGURE 27: GRAPHICAL REPRESENTATION, JAPAN MARKET SIZE 2018 V/S 2025
  • FIGURE 28: GRAPHICAL REPRESENTATION, CHINA MARKET SIZE 2018 V/S 2025
  • FIGURE 29: GRAPHICAL REPRESENTATION, INDIA MARKET SIZE 2018 V/S 2025
  • FIGURE 30: GRAPHICAL REPRESENTATION, BRAZIL MARKET SIZE 2018 V/S 2025
  • FIGURE 31: GRAPHICAL REPRESENTATION, RUSSIA MARKET SIZE 2018 V/S 2025
  • FIGURE 32: GRAPHICAL REPRESENTATION, ROW MARKET SIZE 2018 V/S 2025
  • FIGURE 33: COMPANY FINANCIAL INFORMATION
  • FIGURE 34: COMPANY SWOT ANALYSIS

(ABOVE MENTIONED FIGURES ARE A FEW AMONG THE TOTAL 51 FIGURES IN THE REPORT)

Back to Top